» Articles » PMID: 38611032

Transcription Factors and Markers Related to Epithelial-Mesenchymal Transition and Their Role in Resistance to Therapies in Head and Neck Cancers

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Apr 13
PMID 38611032
Authors
Affiliations
Soon will be listed here.
Abstract

Head and neck cancers (HNCs) are heterogeneous and aggressive tumors of the upper aerodigestive tract. Although various histological types exist, the most common is squamous cell carcinoma (HNSCC). The incidence of HNSCC is increasing, making it an important public health concern. Tumor resistance to contemporary treatments, namely, chemo- and radiotherapy, and the recurrence of the primary tumor after its surgical removal cause huge problems for patients. Despite recent improvements in these treatments, the 5-year survival rate is still relatively low. HNSCCs may develop local lymph node metastases and, in the most advanced cases, also distant metastases. A key process associated with tumor progression and metastasis is epithelial-mesenchymal transition (EMT), when poorly motile epithelial tumor cells acquire motile mesenchymal characteristics. These transition cells can invade different adjacent tissues and finally form metastases. EMT is governed by various transcription factors, including the best-characterized TWIST1 and TWIST2, SNAIL, SLUG, ZEB1, and ZEB2. Here, we highlight the current knowledge of the process of EMT in HNSCC and present the main protein markers associated with it. This review focuses on the transcription factors related to EMT and emphasizes their role in the resistance of HNSCC to current chemo- and radiotherapies. Understanding the role of EMT and the precise molecular mechanisms involved in this process may help with the development of novel anti-cancer therapies for this type of tumor.

Citing Articles

SATB2 promotes radiation resistance of esophageal squamous cell carcinoma by regulating epithelial-to-mesenchymal transition via the Wnt/β-catenin pathway.

Lin C, Wu Y, Qian Y, Li J, He Y, Yu H Front Oncol. 2025; 15:1543426.

PMID: 40078194 PMC: 11896856. DOI: 10.3389/fonc.2025.1543426.


Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial-Mesenchymal Transition.

Blaszczak E, Miziak P, Odrzywolski A, Baran M, Gumbarewicz E, Stepulak A Cancers (Basel). 2025; 17(2).

PMID: 39858010 PMC: 11764116. DOI: 10.3390/cancers17020228.


Acetylation of Histone H3 in Cancer Progression and Prognosis.

Miziak P, Baran M, Borkiewicz L, Trombik T, Stepulak A Int J Mol Sci. 2024; 25(20).

PMID: 39456765 PMC: 11507103. DOI: 10.3390/ijms252010982.


Roles of ZEB1 and ZEB2 in E-cadherin expression and cell aggressiveness in head and neck cancer.

Kinouchi A, Jubashi T, Tatsuno R, Ichikawa J, Sakamoto K, Sakurai D Genes Cells. 2024; 29(12):1131-1143.

PMID: 39362647 PMC: 11609604. DOI: 10.1111/gtc.13167.


Epithelial‑derived head and neck squamous tumourigenesis (Review).

Shirima C, Bleotu C, Spandidos D, El-Naggar A, Gradisteanu Pircalabioru G, Michalopoulos I Oncol Rep. 2024; 52(4).

PMID: 39219259 PMC: 11358675. DOI: 10.3892/or.2024.8800.


References
1.
Zhang J, Cheng Q, Zhou Y, Wang Y, Chen X . Slug is a key mediator of hypoxia induced cadherin switch in HNSCC: correlations with poor prognosis. Oral Oncol. 2013; 49(11):1043-50. DOI: 10.1016/j.oraloncology.2013.08.003. View

2.
Derynck R, Weinberg R . EMT and Cancer: More Than Meets the Eye. Dev Cell. 2019; 49(3):313-316. PMC: 7672963. DOI: 10.1016/j.devcel.2019.04.026. View

3.
Manzanares M, Blanco M, Nieto M . Snail3 orthologues in vertebrates: divergent members of the Snail zinc-finger gene family. Dev Genes Evol. 2003; 214(1):47-53. DOI: 10.1007/s00427-003-0373-1. View

4.
Simpson P . Maternal-Zygotic Gene Interactions during Formation of the Dorsoventral Pattern in Drosophila Embryos. Genetics. 1983; 105(3):615-32. PMC: 1202177. DOI: 10.1093/genetics/105.3.615. View

5.
Zhao J, Zhang L, Dong X, Liu L, Huo L, Chen H . High Expression of Vimentin is Associated With Progression and a Poor Outcome in Glioblastoma. Appl Immunohistochem Mol Morphol. 2016; 26(5):337-344. DOI: 10.1097/PAI.0000000000000420. View